Bausch Health Companies Inc. (BHC)

Market Cap	3.01B
Revenue (ttm)	8.35B
Net Income (ttm)	-186.00M
Shares Out	364.33M
EPS (ttm)	-0.51
PE Ratio	n/a
Forward PE	2.37
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,436,891
Open	8.19
Previous Close	8.22
Day's Range	8.14 - 8.35
52-Week Range	5.57 - 10.23
Beta	0.97
Analysts	Buy
Price Target	12.00 (+45.46%)
Earnings Date	Nov 2, 2023

About BHC

Bausch Health Companies Inc. operates as a diversified pharmaceutical company. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, a...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Thomas J. Appio
• Employees: 19,600
• Stock Exchange: NYSE
• Ticker Symbol: BHC

Financial Performance

In 2022, BHC's revenue was $8.12 billion, a decrease of -3.68% compared to the previous year's $8.43 billion. Losses were -$225.00 million, -76.27% less than in 2021.

Analyst Forecast

According to 3 analysts, the average rating for BHC stock is "Buy." The 12-month stock price forecast is $12.0, which is an increase of 45.46% from the latest price.

Price Target

$12.0

(45.46% upside)

Analyst Consensus: Buy